Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention

by Medindia Content Team on  November 2, 2005 at 7:07 PM Cancer News   - G J E 4
Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention
Study results from two research papers have shown that use of the drug Ospemifene in combination with other anti-estrogens for vaginal atrophy reduces the incidence of breast cancer. The study has been proved in mouse model and researchers are planning for a clinical trial.

DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development. Results show that the mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer and the study result is to be published in the Journal of Steroid Biochemistry and Molecular Biology.

The second study in which the first study author DeGregorio is also a co-author was led by Jeffrey P. Gregg, Associate professor of pathology and laboratory medicine at UC Davis, where they reported that Tamoxifen and Ospemifene both inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ in mouse model.

Ospemifene is a Selective Estrogen Receptor Modulator (SERM), and is an effective anti-estrogen like tamoxifen and raloxifen which is used in the prevention and treatment of breast cancer which binds to estrogens. Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

The advantage of Ospemifene over tamoxifen and raloxifen is due to its reduced side effects as raloxifen can cause hot flashes, insomnia and blood clots. Tamoxifen can cause endometrial cancer in patients undergoing tamoxifen therapy for breast cancer. But ospemifene have a unique estrogen-like effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
I have been taking the drug Ospemifene since February of 2007 in a research for Hormos Medical Corporation. I have severe Vaginal Atrophy. I have shown very good results. I hope this can be put on the market. This is thru the American Health Network of IN,LLC, Avon Clinical Research Department in Avon, IN.
guest Tuesday, September 11, 2007